Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

29.03 0.00 (0.00%)
Streaming Delayed Price 8:00:01 PM GMT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neurogene Inc. - Common Stock

< Previous 1 2 Next >
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
From Neurogene Inc.
Via Business Wire
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces Oversubscribed $200 Million Private Placement
From Neurogene Inc.
Via Business Wire
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene
Via Business Wire
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in BMO Genetic Medicines Summit
From Neurogene Inc.
Via Business Wire
Neurogene Announces Addition to Russell 3000® Index
From Neurogene Inc.
Via Business Wire
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
From Neurogene Inc.
Via Business Wire
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.